Cladding Solutions for Commercial Kitchens: Moisture Resistant Wall Panels from Interstate Plastics

UtiLite Ceiling Panels in a Laboratory.

UtiLite Ceiling Panels in a Laboratory.

UtiLite Ceiling Panels in a Carwash.

UtiLite Ceiling Panels in a Carwash.

Utilite Ceiling Panels in a Fire Station.

Utilite Ceiling Panels in a Fire Station.

Interstate Plastics now offers UtiLite™, a rot, corrosion, and moisture-resistant decorative interlocking wall and ceiling panel.

UtiLite™ can be used anywhere that moisture-resistant panels are needed. They're attractive panels and maintain their high-quality look and feel, even when repeatedly cleaned with harsh chemicals.”

— Christopher Isar

SACRAMENTO, CA, UNITED STATES, March 31, 2021 / — Commercial kitchens are high traffic areas: the risk of spills, wall splatters, and general accidents involving liquids is ever-present, necessitating the use of wall panels that resist stains, rot, and corrosion. For complete coverage against moisture, rot, and corrosion, Interstate Plastics now offers UtiLite™, a completely moisture-resistant interlocking wall and ceiling solution that can also serve as a smooth, decorative kitchen wall panel.

UtiLite™ moisture-resistant wall panels, built around a polypropylene copolymer corrugated plastic core, are lightweight and durable. 100% moisture-resistant UtiLite™ panels do not rot or corrode, making them easy to clean with even the harshest cleaning solutions. These panels have tongue and groove edges that interlock for a smooth, near-seamless appearance when installed. They can be installed very quickly, either vertically or horizontally, directly to studs or substrate, making installation of UtiLite™ a simple process. UtiLite™ panels also reflect 92% of light to keep rooms brightly lit, critical for inspection processes and industrial kitchens. These cost-effective interlocking wall tiles and panels are USDA and FDA compliant and have a Class A fire rating, a must for any commercial kitchen environment.

In addition to commercial kitchens, UtiLite™ can be used anywhere that moisture resistant panels are needed, including for the walls and ceilings of car wash facilities, locker rooms, dairy facilities, food processing plants, medical exam rooms, and laboratories. UtiLite™ has been installed in veterinary clinics, pharmaceutical plants, marine facilities, grow rooms, and even clean rooms.

UtiLite™ is white with a smooth finish. To learn more about UtiLite™ interlocking wall panels and other wall or ceiling cladding solutions for kitchens or businesses, call the experts at Interstate Plastics at (888) 768-5759.

Interstate Plastics is a full-line distributor of plastic sheet, rod, tube, bar, film, and profiles, as well as plastic accessories, tools, and care products. With 10 locations nationwide and an online sales and support team, Interstate Plastics provides full sheets and pallets, simple cut-to-size service, and complex CNC manufacturing. Interstate Plastics is known for its reputation of selling high-quality products, providing excellent customer service, and superior technical support. All of our products and services are available using the safe, secure, and convenient purchasing system on the Interstate Plastics website. For instant help, we're always just a phone call away at (888) 768-5759.

Stephen Sowinski
Interstate Plastics
+1 888-768-5759
email us here
Visit us on social media:

Source: EIN Presswire

Australia’s Most Comprehensive Medicinal Cannabis Report: H1 2021

Intense medicinal cannabis product competition keeps downward pressure on prices as patient numbers grow by a factor of 15x over the past 2 years

SYDNEY, NSW, AUSTRALIA, March 31, 2021 / — FreshLeaf Analytics is excited to once again release Australia’s most comprehensive medicinal cannabis Patient, Product and Pricing Analysis.

The last 6 months were defined by intense medicinal cannabis product competition, keeping a downward pressure on prices – which is good news for patients.

This report will be the sixth major publication from FreshLeaf, which is the leading source of information, data and analysis on the sector.

– Medicinal cannabis revenue expected to exceed expectations in 2021, hitting A$200m+
– Patient numbers have grown by a factor of 15x over the past two years
– Significant increase in “Authorised Prescribers” after long period of stagnation
– Intense product competition continues as new products flood the market, keeping downward pressure on price
– Average daily dose and average monthly spend stabilise
– Slow-down in delivery format innovation with only 1 new format introduced in last 6 months
– Sizeable patient cohort expected to migrate to the pharmacy channel once low-dose CBD products become available over the counter in pharmacies
– 2021 will bring evolution in the regulatory landscape, a greater emphasis on product quality, growing investment in R&D, and further industry consolidation

Cassandra Hunt, Managing Director of FreshLeaf commented: “The Australian medicinal cannabis market continues its strong growth trajectory with revenue expected to more than double in 2021 from around $100m last year. There’s good news for patients too, with the price of medicine continuing to fall.”

Tim Drury, CEO of Southern Cannabis Holdings: “While we’re excited by the continued growth in the industry, the fact that the illegal market is still more than 10 times larger than the legal market means that we still have a long way to go before we can consider that Australia has the right ecosystem for helping patients”.

The report has also been welcomed by the sector, with key players commenting:

Dr Mark Hardy, Addiction Specialist and CA Clinics Medical Director commented: “When you consider that there were only about 3,000 active patients just two years ago, and that FreshLeaf projects that active patient numbers may climb to 75,000 by the end of 2021, clearly more people have been able to gain access to legal medicinal cannabis. It is of the utmost importance that patients have treatment options, and these figures suggest that cannabinoid medicine is increasingly being accepted as a viable option by the mainstream.”

Clare Barker, GM of Entoura said: "The proliferation of medicinal cannabis products to a total of 190 now available for Australian physicians to prescribe seems like a positive for patient choice on the surface, but it also makes it harder for doctors to differentiate between them. This means that product and delivery format innovation is more important than ever. We brought the only new format in the last 6 months to market in the form of chewable tablets, which are proving to be convenient for active patients and may be more palatable for those who dislike the taste of oils or for children”.

And Peter Crock, MCIA Chairman added: "The report shows that the industry is maturing and local product is coming on stream. This will improve with regulatory reforms currently being worked through. The increase in patients also demonstrates the valuable role for medicinal cannabis and reinforces how important it is that the evidence base catches up, and we can bring products through the registration pathway”.

A full copy of the report can be downloaded for free from the FreshLeaf website.

Available for interview:
– Cassandra Hunt, MD FreshLeaf Analytics
– Dr Mark Hardy, Medical Director CA Clinics

For Media Enquiries: AJD Media on or call 0422238809

About FreshLeaf Analytics:
FreshLeaf Analytics, part of the Southern Cannabis Holdings group, is Australia’s leading source of data and information about the medicinal cannabis industry.

FreshLeaf provides strategic consulting services to industry and government clients. For more information: or (+61) 2 8203 8741 @FreshLeafA

About Southern Cannabis Holdings:
SCH specializes in building and operating cannabis businesses in markets where cannabis is regulated as a pharmaceutical product. SCH
companies include CA Clinics, Applied Cannabis Research and FreshLeafAnalytics. To find out more about SCH, please visit

Nisha Sreenivasan
AJD Media
422238809 ext.
Visit us on social media:

Source: EIN Presswire

Parkinson's Education: Free Webinar Series

Wisconsin Parkinson Association provides hope, community, support, and resources for people with Parkinson disease and their loved ones. Learn more at

Paul & Diana Beder live in Waupun, WI. When COVID hit and it wasn’t safe for Paul to attend classes at his local gym, they joined Wisconsin Parkinson Association’s free classes on Facebook Live and Zoom 3 times each week. Exercise is the only way to slow

Wisconsin Parkinson Association is offering a free webinar series for people with Parkinson's.

BROOKFIELD, WISCONSIN, USA, March 31, 2021 / — Parkinson disease is the fastest growing neurological disorder in the US. Over 1 million people have Parkinson’s – more than MS, ALS, and Muscular Dystrophy combined – and in Wisconsin, over 20,000 people live with Parkinson’s.

April is Parkinson’s Awareness Month, and Wisconsin Parkinson Association is sharing crucial education and resources for people who have Parkinson’s, as well as their loved ones.

“Wisconsin Parkinson Association hosts education programs in-person and online throughout the year,” said Gary Garland, executive director for Wisconsin Parkinson Association. “Even if you can’t physically travel to participate, we can bring the education right to your living room.”

This free education includes a webinar series for people who are recently diagnosed with the disease. April 12-16 from noon until 1:00pm each day, Wisconsin Parkinson Association will be hosting a webinar on life with Parkinson’s. Topics will include symptoms and how Parkinson’s is diagnosed, treatment options, mental health issues, and the importance of exercise.

“These programs can really provide a lifeline for someone who just received a Parkinson’s diagnosis,” said Garland. “It’s important for them to know that they are not alone, and this disease is not a death sentence."

The primary symptoms of Parkinson disease are resting tremor, muscle rigidity, slowness of movement, and postural instability. Patients may also experience problems with swallowing, smaller handwriting, constipation, soft or slow speech, stooped posture, depression, and anxiety.

While some patients know where to turn or how to find resources to help them deal with their new diagnosis, many people find themselves feeling alone, hopeless, and without support. Now more than ever, it is crucial for patients and caregivers to stay connected to their peers, find relief from their symptoms, and educate themselves.

To register for the free webinar series, or to find more resources about Parkinson’s, visit or call 414-312-6990.

# # #

About Wisconsin Parkinson Association
Wisconsin Parkinson Association provides hope, community, support, and resources for people with Parkinson’s and their loved ones. Founded in 1984 as an independent 501c3, WPA conducts local and regional education programs about Parkinson disease and provides literature, education materials, and a speaker’s bureau. WPA coordinates community support groups throughout Wisconsin and the surrounding states that assist people with Parkinson disease and their caregivers and families. Visit for a list of over 200 support and exercise groups as well as information about services available to those living with Parkinson disease.

Carolyn Hahn
Wisconsin Parkinson Association
+1 4143126990
email us here
Visit us on social media:

Source: EIN Presswire

New Patient Education Program on Cancer Oral Health Care Noted Nursing Educator, Judith Haber, Ph.D, APRN.

“Oral health side effects have significant physical and emotional negative consequences for patients undergoing chemotherapy, radiation, or immunotherapy that can affect patients’ quality of life.”

— Nursing Educator, Judith Haber, Ph.D., APRN

GoMo Health in collaboration with the Oral Health Nursing Education and Practice (OHNEP) Program has added oral care patient education to its evidence-based Concierge Care® oncology digital therapeutic, filling a much-needed gap in addressing oral care management as part of patient-focused cancer clinical pathways. Recent studies show that the incremental costs alone of oral mucositis was approximately $ 5000–$30,000 among patients receiving radiation therapy and $3700 per cycle among patients receiving chemotherapy.

“Oral health side effects have significant physical and emotional negative consequences for patients undergoing chemotherapy, radiation, or immunotherapy that affect patients’ health and quality of life and can lead to increased adverse events and cost. However, oral health is frequently overlooked in clinical pathways and outpatient care,” says noted Nursing Educator, Judith Haber, Ph.D., APRN, FAAN, the NYU Ursula Springer Leadership Professor in Nursing and Executive Director of the Oral Health Nursing Education and Practice (OHNEP) Program.

The Concierge program provides oral care management messaging to oncology patients to prevent the onset of oral side effects from their treatment and for those who may already be experiencing issues. Once indicating their oral care issues through the Concierge program’s version of the NCCN Distress Thermometer and Problem List, the How Are You Doing?TM survey, patients automatically receive support and actionable tips to relieve discomfort from symptoms like dry mouth, mouth sores, bleeding gums, and gum disease.

Nursing Educator, Judith Haber, Ph.D, APRN, is available for interviews via Zoom-SKYPE-FaceTime
Contact: Fred Yaeger (914) 525-9198

The oral care content adds valuable resources to the existing Concierge Care program that is working in tandem with nurse navigation, pharmacy, and social work to help guide a patient and their family through emotional, social/practical, and physical challenges during cancer journey. For more information about the GoMo Health Oncology Digital Therapeutic, click here.

About GoMo Health: GoMo Health® applies a proprietary, evidence-based science of engagement, BehavioralRx®, to our cloud-based digital therapeutic, Concierge Care®, to actively extend care plans, and provide resources and support in a person’s “lived” environment – enhancing outpatient care and impact. This outpatient care delivery model integrates support for psychosocial and physical needs to create personalized, behaviorally based care plans that empower patients in their own care management and healthy decision making. Connecting with patients via its’ Telehealth Triple Play™, GoMo Health using an intelligent mobile BOT to collect and triage patient data via home medical devices, conduct in the moment “conversations”, and gather electronic patient-reported outcomes (ePRO). This has proven to modify behaviors of patients with chronic and complex conditions worldwide, resulting in significant improvement in health outcomes and adherence, and decreased costs of care for providers, hospitals, health plans, employers, and life science companies.

The Oral Health Nursing Education and Practice (OHNEP) Program, at New York University’s School of Nursing, is a core partner of the National Interprofessional Initiative on Oral Health (NIIOH), and is a unique national initiative that aims to enhance the nursing profession’s interprofessional role in oral health and its links to overall health in both academic and clinical settings. Funded by the DentaQuest Partnership for Oral Health Advancement and the Arcora Foundation, OHNEP aims to integrate interprofessional oral health content and competencies for the nation’s 4.2 million nurses in undergraduate and graduate nursing programs through faculty and preceptor development, curriculum integration, and establishment of “best practices” in clinical settings.

Fred Yaeger
Yaeger Public Relations
+ +1 914-525-9198

Source: EIN Presswire

Phase Two Magdi Yacoub Global Heart Centre Announcement

The Magdi Yacoub Global Heart Foundation is positioning its new Global Heart Centre as a transformative potential across the region, philanthropic support.

Your Gift will Save LIVES. Please join us today and add your name as a legacy in Magdi Yacoub Global Heart Centre. Together we will save lives.”

— Reda S. Athanasios


The Magdi Yacoub Global Heart Foundation is positioning its new Cairo-based Global Heart Centre as a revolutionary project with transformative potential across the region, making it an appealing candidate for philanthropic support.

The Magdi Yacoub Global Heart Foundation Board is pleased to announce the commencement of phase two in the construction of the Magdi Yacoub Global Heart Centre-Cairo (MYGHC). Located in the modern 6th of October City, the center is expected to open doors in 2023 and provide free-of-charge, world-class heart care to underprivileged patients. It was a needed expansion to cope with the overwhelming demand facing the highly successful Aswan Heart Centre. MYGHC is a high-impact prospect for philanthropic support and is projected to transform the heartcare landscape by strongly impacting heartcare outcomes for the most vulnerable, particularly children, across Egypt, and the broader Middle East, and Africa.

The work of Prof Magdi Yacoub and his medical teams at the Aswan Heart Centre has been covered extensively in global media, and the tremendous impact of that revolutionary endeavor has given our hospital and its broad mission exposure across high-profile media outlets across the world. The Aswan Heart Centre, and its continuing success, occurred through our successful relationships with our supporters. The Magdi Yacoub Global Heart Foundation established and nurtured proud and lasting partnerships with philanthropists across the United States and beyond.

“It was our honor to have this opportunity to be part of Prof. Magdi Yacoub’s humanitarian mission to help our needy fellow Egyptians,” expressed Hoda & Cameel Halim of Chicago, long-time supporters of the Aswan Heart Centre. “Prof. Yacoub has given us a valuable lesson in giving, and we hope that all of us around the world will join him in making his continuing work highly successful.”

Chairman of the Board, Magdy Ishak, said, “The Board and the management team are proud of what we have achieved with partners like Mr. and Mrs. Halim and others. We believe that Aswan Heart Centre, with its successful integration of quality clinical care, innovative research, and excellent training in Egypt, serves as an inspiration to others of what can be possible for the future of global healthcare. Our new center will extend our capacity and reach both in Egypt and Africa.”

At this point, we are seeking philanthropic patronage for the Magdi Yacoub Global Heart Centre-Cairo. This new Center in Cairo, the most significant metropolitan hub in the entire region, vastly expands our impact. Upon its completion in 2023, the new Magdi Yacoub Global Heart Centre will be offering free-of-charge cardiovascular services with a capacity of 120,000 outpatients and 12,000 procedures annually. It will host five operating rooms and five catheterization laboratories. It will include a hybrid room, a state-of-the-art imaging center, world-class 5000-square meter research and innovation laboratories, a 4000-square meter education and training facility, as well as an Emergency Department.

About Magdi Yacoub Heart Foundation
The Magdi Yacoub Global Heart Foundation–A U.S.-based 501c3 charity–was founded by Professor Sir Magdi Yacoub. The MYGHF is committed to changing the most vulnerable health outcomes in Egypt and the broader Middle East and Africa, particularly children, by providing comprehensive, advanced cardiac care available to all people in need, free of charge. The Aswan Heart Centre (AHC) is a facility operated and funded with the support of MYGHF. It has achieved regional and international recognition as a Center of Excellence for the treatment and research of cardiovascular diseases. The Aswan Heart Centre (AHC) and the new Magdi Yacoub Global Heart Centre Cairo are operated and funded with the support of MYGHF. Both centers depend on philanthropic support and provide all their services free of charge.

Reda Athanasios
Magdi Yacoub Global Heart Foundation
+1 415-495-1064
Visit us on social media:

Naming opportunity at new Center

Source: EIN Presswire


Dr. Rob Headrick Introduces ‘Second Wind Society’

Second Wind Society Launches Facebook Page to Provide Support for Patients and Caregivers


“We’ve developed best practices for our lung program that can be applied anywhere in the country. Over the last 18 months, we have data showing this model not only works, but works well.” ”

— Dr. Rob Headrick

CHATTANOOGA, TN, USA, March 31, 2021 / — Dr. Rob Headrick has spent his career dedicated to lung cancer. His passion for his patients led to the development of technology to promote efficient mobile screenings; however, he realized that care for these individuals often meant so much more.

“Healthcare constantly changes and we have to be adept in meeting those needs. The mobile unit does this, but there’s another critical piece to the puzzle and that’s in addressing the needs of supporting those patients.”

Headrick found that families, friends and caregivers of patients are often stressed in meeting the needs of loved ones. Some are forced to take a leave of absence from their jobs to care for patients while others are faced with the knowledge that the primary wage earner for the family is dying of cancer. His passion led to an additional purpose: that of supporting patients and those who provide support and care to them.

Throughout the cancer journey, patients and their caregivers have few places to turn for resources. He recently launched the ‘Second Wind Society’ with the goal of providing a resource and place to connect with others willing to share their experiences. Headrick said, “Lung cancer can literally take your breath away, but this group is here to support patients and those caring for them.” Members of the group come from across the country as well as from outside of the U.S. and while they may never meet personally, they know that they now have a resource for their questions and people who are joining them on their journey.

Rita Haskew serves as the conduit for the group. She noted, “Individuals are joining our group every day. They come to us from across the country. Some are patients while others are part of their support system. The commonality they all have is the impact on their lives from lung cancer. Our hope is that they know that this group is a place to ask questions, seek additional support and share experiences along the way.”

The group’s Facebook page, Second Wind Society, allows those impacted by lung cancer to meet in a private group setting. From requests for prayer about an upcoming scan to questions about traveling while being treated, the group shares experiences and offers support.

One member recently posted, “Wow! I was about to say I can't believe the outpouring of prayers and thoughts for my family, but then again, I thought, there's nothing unusual about it. That's how special this group is. [But] I can't begin to thank all of you enough for those thoughts and prayers they truly mean a great deal to my wife and myself and my brother and sisters and their spouses.”

Headrick shares that the group came out of a need to provide and expand services to those impacted by a cancer that is the leading cause of cancer death among both men and women, making up almost 25% of all deaths. Individuals in the U.S. die of lung cancer over breast, colon, and prostate cancers combined. Only 2% of eligible patients participate in available screening. With these statistics and facing the mounting numbers of lung cancer cases coming into his own practice, the Chattanooga, Tennessee-based thoracic surgeon developed a program to screen individuals without them having to come into healthcare facilities.

His team found that while individuals living in more rural areas were concerned about their health, they were not willing to come to hospitals or physician offices, especially during the current pandemic. With so many rural hospitals closing, options for care were becoming increasingly limited. The amount of time taken to complete paperwork and waiting times also added into their concerns and they simply chose to put their health on hold.

Dr. Headrick gathered a team of engineers, healthcare professionals, and industry leaders to develop a mobile unit that could go into communities to provide screenings. Working together, they determined that while individuals might not feel comfortable in more formal settings, they would come out to favorite quick serve restaurants in their communities if they knew they could be quickly and easily screened.

The mobile screening unit consists of a Siemens 64 slice CT scanner and separate waiting area. The staff consists of a driver/ registrar, radiology technician, and advanced practice provider. Individuals enter the unit to complete their paperwork and are then screened. Using the results from the LDCT (Low Dose Computed Tomography) imaging, early lung cancer is easily detected.

Today, the unit travels throughout southeast Tennessee and northwest Georgia with a team of professionals to serve patients. In the midst of the pandemic, they found that the mobile unit has another very valuable use that could be put into play by being deployed to provide vaccine throughout these same rural counties.

Dr. Headrick explains, “We’ve been able to develop best practices around our lung program that can be applied anywhere in the country. Over the last 18 months of operations, we have the data to show this model not only works, but works well.” He added that the program is well-positioned for replication across the country and that his team is available to support growing efforts.

Headrick shared that the combination of having screening readily available and providing support after the diagnosis is incredibly helpful to patients and their caregivers. “At its earliest stages, lung cancer has no symptoms. We know that if we can get screens done early, we can cure lung cancer. The model we’ve built combining accessibility to technology on the front end to emotional and logistical support after the diagnosis saves lives.”

To receive additional information or to book Dr. Headrick for speaking engagements, contact or call: 423.755.7588. To learn more about Dr. Headrick visit, @Dr.RobHeadrick on Facebook or the Second Wind Society.

Robin Derryberry
Derryberry PR
+1 423-667-1106
email us here
Visit us on social media:

Source: EIN Presswire

C4 Imaging Announces Addition to Board of Directors

C4 Imaging LLC, an early-stage medical device company, has announced that Jeff Seavey has been elected to the company's Board of Directors.

We are pleased to welcome Jeff to our Board at an important time for C4 Imaging. Jeff is a highly respected and seasoned medical device leader and will be an excellent resource for the C4 team.”

— Andrew Bright

HOUSTON, TX, USA, March 31, 2021 / — C4 Imaging LLC, an early-stage medical device company, has announced that Jeff Seavey has been elected to the company's Board of Directors. Jeff joins the C4 Imaging Board with over 25 years of success in the development and commercialization of medical devices.

Jeff graduated from Texas A&M University with a BS in Engineering and he currently serves as President and CEO of MakrMed LLC. His previous experience includes a diverse blend of executive roles, research and development leadership, global sales and marketing success. He was President and CEO of Restore Surgical LLC, dba Instratek from 2007-2016, where he built a highly successful medical device manufacturing business, with a worldwide distribution network. Instratek was acquired by Stryker Corporation in 2016.

"We are pleased to welcome Jeff to our Board at an important time for C4 Imaging,” said Andrew Bright, C4 Imaging’s President and CEO. “Jeff is a highly respected and seasoned medical device industry leader and will be an excellent resource for the C4 team as we prepare to launch Nova™, our recently FDA 510(k) cleared multimodality fiducial marker.”

"I am excited to join C4 Imaging’s Board," stated Mr. Seavey. "I look forward to working with my fellow Board members and company management to help deliver the benefits of C4’s unique positive-signal MRI technology to the many cancer patients who would benefit from it."

For further information:

Andrew Bright
Tel: 609 933 5895


C4 Imaging develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company’s proprietary technology, C4, has been developed as Sirius®, a positive-signal MRI marker designed to improve quality assessment after prostate cancer treatment with brachytherapy, as well as Orion™, an MRI marker that enables accurate MRI–based pre-treatment planning for cancer patients being treated with high dose rate (HDR) brachytherapy. Sirius® and Orion™ enable the adoption of MARS – MRI-Assisted RadioSurgery. C4’s multimodality fiducial marker, Nova™, was recently FDA cleared and will be launched in 2021; Nova™ will allow the benefits of positive-signal MRI treatment management to be offered to the hundreds of thousands of patients who receive radiotherapy each year. C4 are currently developing non-metallic, positive MRI signal products specifically designed for the breast cancer biopsy market. To learn more, please visit Join us on Facebook/siriusmri.

Copyright © 2021
Orion, Sirius and Nova are trademarks of C4 Imaging

Andrew Bright
C4 Imaging
+1 6099335895
Visit us on social media:

Source: EIN Presswire

XtremeLabs and Wiley Publish New AWS Lab Bundles

Logo for XtremeLabs LLC - Digital IT experiential learning platform

XtremeLabs LLC – Digital IT experiential learning platform

XtremeLabs Continues Partnership with Wiley to Create Hands-On Labs for AWS Titles

We are especially excited about the AWS study guides and lab bundles being adopted by some of the largest academic institutions as part of their cloud skills curriculum.”

— Judy Zhang, Product Manager, XtremeLabs LLC

MCLEAN, VIRGINIA, USA, March 31, 2021 / — XtremeLabs LLC, an award-winning creator of digital hands-on learning labs announced the availability of two new titles under the Wiley Sybex label with bundled online labs.

AWS Certified Data Analytics Study Guide with Online Labs: Specialty DAS-C01 Exam (ISBN: 978-1-119-81945-5) prepares students and professionals for the AWS Data Analytics DAS-C01 certification exam. The bundled labs provide students with over 75 hands on exercises.

AWS Certified Solutions Architect Study Guide with Online Labs: Associate SAA-C02 Exam, 3rd Edition (ISBN: 978-1-119-81947-9) is the newest edition of the Solutions Architect bundle that helps prepare for the AWS Solutions Architect SAA-C02 Exam. The bundled labs provide students with over 14 modules of hands exercises.

In July 2020, XtremeLabs partnered to release three titles that included a Wiley Sybex AWS book along with access to XtremeLabs custom learning labs. The three titles included:

-AWS Certified Solutions Architect (ISBN: 978-1-119-75612-5)
-AWS Certified SysOps Administrator (ISBN 978-1-119-75669-9)
-AWS Certified Cloud Practitioner (ISBN 978-1-119-75670-5)

“Since last summer, learners have launched thousands of labs to develop and practice AWS skills,” said Judy Zhang, Product Manager at XtremeLabs. “We are especially excited about the AWS study guides with online lab bundles being adopted by some of the largest academic institutions as part of their cloud skills curriculum."

XtremeLabs was awarded the 2020 Platinum Learning Impact Award by the IMS Global Learning Consortium, demonstrating innovation in the education industry for its Digital Hands on Learning Labs in partnership with the Southern Alberta Institute of Technology’s FAST Track IT Programs.. XtremeLabs has also been a recipient of Training Industry Watch List of Training Delivery companies and received 4 IBA Stevie Awards in the Workforce Readiness and Computer Products category.

XtremeLabs provides technology products and services to support employability, workforce development and training. XtremeLabs provides hands-on labs for training, examinations and certifications. XtremeLabs has over 12000 hands-on labs that cover subjects such as coding, security, data science, machine learning, networking. and other technologies. For more information you can visit our website at

Sana Rehmat
XtremeLabs LLC
+1 425-654-7441
email us here
Visit us on social media:

Source: EIN Presswire

ChinaBio® Partnering Forum goes hybrid in May to accelerate cross-border life science partnerships globally

ChinaBio® Partnering Forum | May 10–14, 2021 | Shanghai and Digital

ChinaBio® Partnering Forum | May 10–14, 2021 | Shanghai and Digital

ChinaBio® Partnering Forum | Two days in-person

ChinaBio® Partnering Forum | Two days in-person

ChinaBio Partnering Forum | Three days virtually

ChinaBio Partnering Forum | Three days virtually

CARLSBAD, CA, UNITED STATES, March 31, 2021 / — The thirteenth annual ChinaBio® Partnering Forum will be held May 10–14, 2021, in a hybrid format; two days in-person in Shanghai, three days virtually, with a global reach enabling unprecedented partnering opportunities between companies worldwide and China’s fastest growing international healthcare market. The event is the largest and most well-established life science partnering conference spotlighting China, and its expanded five-day format with longer hours during the virtual portion of the event will allow widespread participation.

Registration and partnering details are available online.

“This is a prime time to take advantage of valuable opportunities with new partners and investors in China, without having to travel,” said Greg B. Scott, Founder and Chairman, ChinaBio® Group. “The event is the most important in China for connecting pharma and investors with China innovation and manufacturing, featuring a strong increase in important licensing deals with Western companies.”

“At a time when face-to-face interactions continue to be limited, we must find new approaches and creative solutions for fostering and maintaining the critical relationships that drive life science partnering, company growth and much needed therapeutics forward,” said Tina Gunnink, Managing Director, EBD US. “Our unparalleled partnering system facilitates seamless virtual meetings across the world through a video platform that allows person-to-person partnering.”

Companies, organizations and researchers interested in presenting their technologies or products available for partnering can apply to present now. Presentations will be pre-recorded and available to all registered delegates before and during the event.

ChinaBio® Partnering Forum is hosted by ATLATL and sponsored by Ascentage, BioDuro/Sundia, Bio2 Innovation Center, Boehringer Ingelheim, Cooley, Cytovance Biologics, Flanders Investment & Trade, Global Victoria, Hitgen, Johnson & Johnson Innovation, Luoxin, Morrison Foerster, MSD, Pfizer, PRA Health Sciences, Roche, Sanofi-Aventis Groupe, Shanghai Lingang Economic Development Group Technology Investment Co., Ltd., Vetter Pharma and Visen Pharma.

Attending companies from China and across the globe include pharma, biotech, innovative startups, and researchers from leading universities and institutes, as well as VCs and other industry stakeholders.

Partnering information for ChinaBio® Partnering Forum is available online. Registration rates increase on April 2, 2021, information is available online.

Follow ChinaBio® Partnering Forum on Twitter:  @EBDGroup (hashtag: #ChinaBioPartnering).


About EBD Group  
EBD Group's overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. 

Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, Imagine Health Summit, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. 

 EBD Group is an Informa company. For more information please visit 

About ChinaBio® Group
Since its founding in 2007, ChinaBio® Group has successfully helped nearly 100 US, European and Asia-Pacific life science companies achieve success in China. Leveraging its consulting and advisory teams’ significant experience in China’s life science industry, ChinaBio® has helped its clients identify over 1,000 in-/out-licensing and M&A opportunities and raise over $500M in funding in China. Clients have included many global pharma and life science companies as well as early stage and mid-size companies in Europe, US, Korea and Japan, as well as China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, and publishes ChinaBio® Today, the most widely read source for China life science news. ChinaBio® Group is headquartered in Shanghai with staff in San Diego, Silicon Valley, Canada and Switzerland.

Susanna Ling
EBD Group
+1 760-930-0500
email us here
Visit us on social media:

Source: EIN Presswire

CEOCFO Magazine interviews MediPines CEO Steve Lee on revolutionizing Respiratory Medicine with their AGM100™

MediPines logo

MediPines AGM100™ Product

MediPines AGM100™

CEOCFO Magazine logo

MediPines CEO & Founder Steve Lee on Non-Invasively providing Instant Pulmonary Gas Exchange Measurements Using a Simple Patient Breathing Method

Hospital providers that leveraged the AGM100™ have reported dramatic results, such as reduced ICU admission rates.”

— Steve Lee

YORBA LINDA, CALIFORNIA, US, March 31, 2021 / — CEOCFO Magazine, an independent business and investor publication that highlights important technologies and companies, today announced an interview ( with Steve Lee, CEO and Founder of medical device company MediPines, headquartered in Yorba Linda, CA. “Hospital providers that leveraged the AGM100™ have reported dramatic results, such as reduced ICU admission rates. According to one Midwest provider, the hospitalized COVID-19 patient death rates plummeted after adoption of the AGM100.” Mr. Lee shared with CEOCFO’s Bud Wayne the MediPines mission, when they were founded and how long their AGM100 has been on the market, “The AGM100 is the world’s first FDA cleared respiratory system that non-invasively provides pulmonary gas exchange measurements using a simple patient breathing method. It is a portable system that can be used at the bedside. I view it as a portable pulmonary lab in a box. In 2015, I launched MediPines with outside investment from prominent Silicon Valley investors. The founding mission of MediPines is to advance respiratory medicine. AGM100 was commercially released five years later in 2020 and it is rapidly being adopted across the country in many leading hospitals, today.”

Asked why they decided to focus on respiratory medicine Mr. Lee told us, “This rising tide of respiratory diseases was, in part, due to the pre-existing prevalence of respiratory diseases like COPD and asthma, combined with different factors like the aging population, occupational exposure, and air pollution. Now that the COVID-19 pandemic is here, the world is even more aware of the risks from respiratory-related illnesses.”

Explaining the AGM100’s ease of use Mr. Lee said, “It’s non-invasive. A patient simply needs to breathe through a specialized mouthpiece that is connected to our analyzer unit. The measurement is not difficult or dependent upon patient effort, the patient just needs to breathe. It is easy for the patient and convenient for the clinician to operate.”

In the interview Mr. Lee shared why he feels their product is so critical in the hospital environment, "It helps provide answers to essential respiratory questions. What is the patient’s blood oxygen level? Is ventilation adequate? Is gas transport from the lungs to the blood efficient? And what is the source of impairment? These are hard questions a clinical team needs answers to, right away, when they are faced with time-sensitive, imminent respiratory failure, or fast-declining patient cases in front of them.” He continued, “The output parameters are immediately actionable to an attending healthcare team. It is used to rapidly assess patient respiratory status, support triage, titrate interventions, and quickly determine response to therapy.”

Discussing a potential pediatric application, “Right now, the AGM100 is FDA cleared for use only in adult populations. However, significant potential pediatric applications are being explored because our device is non-invasive and it may allow pediatric populations to be evaluated in a much more non-invasive manner, which reduces the possibility of pain for kids. MediPines won a competitive award last year funded by Children’s National Hospital and the FDA to study the utility of non-invasive pulmonary gas exchange measurement in pediatric populations,” said Mr. Lee.

As for their geographic reach, Mr. Lee told CEOCFO, “Currently we are cleared for the US market and Health Canada approved us for COVID-19, so we are in North America. Our device is manufactured in Orange County, California in our MDSAP ISO 13485:2016 facility; a global standard for Medical Device manufacturing. We are currently focused on the US and Canada and have a plan to expand to Europe and Asia.”

Mr. Lee shared his thoughts on why MediPines is important to the future of healthcare and patient care, “Respiratory advancement is the key to better human health and managing our future healthcare burden. If we can make improvements in advancing respiratory medicine, this could be one important step to solving a looming healthcare crisis. The success of private sector efforts, like MediPines, could also tell how well we are going to manage our way out of the looming healthcare crisis. Right now, US healthcare consumes 18% of the national GDP. That is $3.8 trillion a year, a staggering number, a substantial economic burden to any society. Medical technology and innovation, I believe, can play an important role in this area. Leveraging the AGM100 can provide 60 times the operating advantage to any hospital provider, compared to the closest alternatives with far fewer resources.”

Mr. Lee continues, “There are some great developments on the vaccine front, but respiratory viruses will continually evolve and raise prospects for future pandemics. Therefore, the continuous research and development in the respiratory field is a vitally important topic for all of us. We are hoping that novel and efficient technologies, like the MediPines AGM100, which I believe is a life-saving innovation, can help blunt the effect of future pandemics, while establishing a solid foundation for better respiratory patient care in the context of this emerging respiratory tsunami. We want to help advance respiratory medicine for the patients and for better healthcare for society.”

Bud Wayne
CEOCFO Magazine
+1 570-851-1745
email us here

Source: EIN Presswire